IP Library Granted Patent US 10,519,498
Granted Patent B2
US 10,519,498 · App. 15/427,718 · Granted Dec 31, 2019

Additives to improve sequencing by synthesis performance

Inventor: James J. DiMeo (Needham, MA)
Assignee: Qiagen Sciences, LLC
C12Q1/6874C12Q1/6869
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,519,498
App. No.
15/427,718
Granted
Dec 31, 2019
Kind
B2
Abstract

The invention relates to methods, compositions, devices, systems and kits are described including, without limitation, reagents and mixtures, for determining the identity of nucleic acids in nucleotide sequences using, for example, data obtained from sequencing by synthesis methods.

Claims (14)

1. A method of incorporating nucleotides, comprising:

a) providing i) a plurality of nucleic acid primers and template molecules, ii) an extend reagent comprising polymerase and a plurality of nucleotide analogues, and iii) a wash reagent comprising methylenediphosphonic acid;

b) hybridizing at least a portion of said primers to at least a portion of said template molecules so as to create hybridized primers;

c) exposing said hybridized primers to said extend reagent under conditions such that a first nucleotide analogue is incorporated into at least a portion of said hybridized primers so as to create extended primers comprising an incorporated nucleotide analogue;

d) washing said extended primers with said wash reagent.

2. The method of claim 1 , wherein said incorporated nucleotide analogue comprises a label attached through a cleavable disulfide linker to the base.

3. The method of claim 2 , wherein said label is fluorescent.

4. The method of claim 2 , wherein said extend reagent further comprises cystamine.

5. The method of claim 2 , further comprising:

e) detecting said label of a first labeled nucleotide analogue.

6. The method of claim 5 , wherein said detecting of step e) is performed in the presence of methylenediphosphonic acid.

7. The method of claim 1 , wherein the concentration of said methylenediphosphonic acid is between 0.1 mM and 4 mM.

8. The method of claim 1 , wherein the concentration of said methylenediphosphonic acid is between 0.25 mM and 1 mM.

9. The method of claim 1 , wherein the concentration of said methylenediphosphonic acid is between 0.35 mM and 0.65 mM.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Mar 24, 2023
From: PERCEPTIVE CREDIT HOLDINGS III, LP
To: ISOPLEXIS CORPORATION
Reel/Frame 063235/0942 →
PATENT PURCHASE AGREEMENT Recorded Jul 30, 2021
From: QIAGEN SCIENCES, LLC
To: ISOPLEXIS CORPORATION
Reel/Frame 057043/0629 →
SECURITY AGREEMENT Recorded May 28, 2021
From: ISOPLEXIS CORPORATION
To: PERCEPTIVE CREDIT HOLDINGS III, LP
Reel/Frame 056421/0929 →
MERGER Recorded Nov 8, 2018
From: QIAGEN WALTHAM, INC.
To: QIAGEN SCIENCES, LLC
Reel/Frame 047923/0815 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2018
From: DIMEO, JAMES J.
To: QIAGEN WALTHAM, INC.
Reel/Frame 045781/0088 →
Continuity (2)
Provisional Application 62293982 · Feb 11, 2016
Related Publication 20170233805A1 · Aug 17, 2017